The alcohol use disorder market was valued at USD 843.45 Million in 2024, driven by the increasing prevalence of alcohol use across the 8 major markets. The market is expected to grow at a CAGR of 6.20% during the forecast period of2025-2034, with the values likely to reach USD 1539.23 Million by 2034.
Base Year
Historical Year
Forecast Year
The market is expected to grow significantly due to increasing alcohol consumption and rising public health initiatives promoting awareness and treatment.
Continuous advancements in pharmacotherapy and personalised medicine are likely to drive innovations and improve treatment outcomes, expanding the market scope.
The adoption of integrated treatment approaches combining medication, behavioral therapies, and support systems is anticipated to enhance treatment efficacy and patient adherence, fueling market expansion.
Alcohol use disorder (AUD) is a medical condition characterized by an impaired ability to stop or control alcohol use despite adverse social, occupational, or health consequences. It ranges from mild to severe and can include symptoms like cravings, withdrawal, and a high tolerance for alcohol.
Growing Awareness and Emphasis on Public Health to Boost Market Growth
Rising public awareness about alcohol misuse and increasing health campaigns are key drivers of the alcohol use disorder (AUD) market. For instance, in June 2024, the World Health Organization (WHO) released a global status report on alcohol and substance use disorders, revealing that 2.6 million deaths annually are attributed to alcohol consumption, with men disproportionately affected. This report underscores the urgent need for comprehensive interventions, which is expected to drive the development of effective treatments and strategies. As the spotlight on AUD grows, demand for innovative therapies and services is projected to fuel market growth during the forecast period.
Advent of New Therapies to Meet Rising Alcohol Use Disorder Market Demand
The growing demand for novel therapeutic approaches and the integration of psychological therapies into AUD treatment are driving innovation in the market. For instance, in August 2024, in a landmark phase III trial, the UK’s National Health Service (NHS) will be investigating ketamine-assisted therapy for preventing alcohol relapse, combining low-dose ketamine infusions with psychological support. Covering 280 adults across multiple NHS sites, this trial is aimed at establishing a groundbreaking treatment model. If successful, the introduction of ketamine-assisted therapy could revolutionise AUD treatment, expand therapeutic portfolios, and significantly drive market development by meeting the unmet needs of severe AUD patients during the forecast period.
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Disorder Type
Market Breakup by Treatment Type
Market Breakup by End User
Market Breakup by Region
Market Segmentation Based on Disorder Type to Witness Growth
The market share is dominated by the alcohol dependence segment, attributed to the higher prevalence of alcohol dependence compared to other types of disorders, such as alcohol abuse or addiction. Alcohol dependence is often characterized by a strong physical desire to consume alcohol, which leads to significant healthcare needs and treatment services. This segment's growth is driven by increasing recognition of alcohol dependence as a medical condition that requires comprehensive treatment strategies, including medication, counseling, and support services, fueling the demand for effective solutions.
The United States leads the regional market share, primarily due to its high prevalence of alcohol use disorder, significant healthcare spending, and robust access to treatment options. The U.S. market benefits from a strong presence of major pharmaceutical companies actively developing treatments, coupled with widespread awareness and a solid healthcare infrastructure supporting early diagnosis and intervention. This region also sees substantial investment in research and development, promoting innovations in therapy and drug development to tackle alcohol dependency effectively.
The key features of the market report comprise clinical trials analysis, patent analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Alkermes plc is a biopharmaceutical company headquartered in Dublin, Ireland, established in 1987. Alkermes offers Vivitrol, a once-monthly injectable formulation of naltrexone that helps prevent relapse in patients after they have detoxified. This product is part of a broader portfolio focusing on central nervous system disorders.
BioCorRx, Inc. is a U.S.-based healthcare solutions company founded in 2008, headquartered in Anaheim, California. BioCorRx is known for its BioCorRx Recovery Program, a comprehensive treatment solution for alcohol and opioid addiction, which includes counselling and medication-assisted treatment featuring naltrexone implants.
Ethypharm is a pharmaceutical company headquartered in Saint-Cloud, France, founded in 1977. Ethypharm provides Selincro, an oral medication containing nalmefene designed to reduce alcohol consumption in adults with alcohol dependence who have a high drinking risk level, without physical withdrawal symptoms and who do not require immediate detoxification. This product forms a part of Ethypharm's broader portfolio, which includes a focus on addiction treatment alongside other therapeutic areas.
INDIVIOR is a pharmaceutical company based in Slough, UK, established in 1994. INDIVIOR offers products like Sublocade and Subutex, which are primarily aimed at opioid dependence but also have applications in treating alcohol use disorder through comprehensive medication-assisted treatment strategies, focusing on both physical and psychological aspects of addiction.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Omeros Corporation, Kinnov Therapeutics, and Adial Pharmaceuticals.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2024 |
| Historical Period | 2018-2024 |
| Forecast Period | 2025-2034 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Disorder Type |
|
| Breakup by Treatment Type |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,969
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share